Brief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
15/10/2026 22:07
BRIEF-Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028 Oct 15 (Reuters) - Crescent Biopharma, Inc. CBIO.O:
CRESCENT BIOPHARMA - POTENTIAL TO INITIATE FIRST CR-001 PHASE 3 STUDY IN EARLY 2028
CRESCENT BIOPHARMA - MULTIPLE SAC-TMT PLUS CR-001 PHASE 2 STUDIES ONGOING IN OVER 700 PATIENTS; DATA MID-2027
CRESCENT BIOPHARMA -ON TRACK TO REPORT INITIAL MONOTHERAPY DATA FROM ASCEND IN Q1 2027, INCLUDING ANTITUMOR RESPONSE FOR FIRST-LINE NSCLC COHORT
CRESCENT BIOPHARMA - APOLLO PHASE 1/2 TRIAL OF CR-002 TO COMMENCE DOSING THIS QUARTER; DATA H2 2027
CRESCENT BIOPHARMA - PHASE 1/2 TRIAL OF CR-003 ONGOING IN CHINA; INITIAL DATA EXPECTED Q1 2027
Source text: ID:nGNX14V3QK
Further company coverage: CBIO.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering